Jump to content

1cP-LSD

From Wikipedia, the free encyclopedia

1cP-LSD
Clinical data
Other names1-CPA-LSD; 1-cyclopropanoyl-LSD; 1-(Cyclopropylmethanoyl)-LSD; 1cP;
Routes of
administration		Oral
Drug classSerotonergic psychedelic; Hallucinogen
Legal status
Legal status
Identifiers
  • (6aR,9R)-N,N-diethyl-7-methyl-4-cyclopropylmethanoyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC24H29N3O2
Molar mass391.515 g·mol−1
3D model (JSmol)
  • CCN(CC)C(=O)[C@@H]5C=C2[C@@H](Cc3cn(C(=O)C1CC1)c4cccc2c34)N(C)C5
  • InChI=1S/C24H29N3O2/c1-4-26(5-2)23(28)17-11-19-18-7-6-8-20-22(18)16(12-21(19)25(3)13-17)14-27(20)24(29)15-9-10-15/h6-8,11,14-15,17,21H,4-5,9-10,12-13H2,1-3H3/t17-,21-/m1/s1
  • Key:RAFUPYYDHPFASC-DYESRHJHSA-N

1cP-LSD, or 1-CPA-LSD, also known as 1-cyclopropanoyl-LSD, is a psychedelic drug of the lysergamide family and an acylated derivative of lysergic acid diethylamide (LSD) which has been sold as a designer drug.[1][2][3] It is a prodrug of LSD.[1]

Use and effects

[edit]

1cP-LSD has been used in the form of blotter tabs containing 100 μg 1cP-LSD free base and pellets containing 150 μg 1cP-LSD hemitartrate.[1]

Interactions

[edit]
See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]

1cP-LSD is a prodrug of LSD.[1] It has been found to produce psychedelic-like effects, specifically the head-twitch response, in rodents with similar potency as 1P-LSD.[1]

Chemistry

[edit]

Analogues

[edit]

Related compounds include 1B-LSD, 1DD-LSD, 1P-LSD, 1V-LSD, ALD-52 (1A-LSD), 1cP-AL-LAD, AL-LAD, ETH-LAD, 1P-ETH-LAD, PRO-LAD, LSM-775, and LSZ, among others.

History

[edit]

1cP-LSD was first synthesized as a legal LSD alternative by Lizard Labs, a Netherlands based research chemical laboratory.[citation needed]

Society and culture

[edit]
[edit]
1cP-LSD on blotter paper.

Sweden

[edit]

Sweden's public health agency suggested classifying 1cP-LSD as a dangerous substance on 18 December 2019 and later classified it as such on 22 April 2021.[4][5]

Research

[edit]

1cP-LSD has been investigated as a potential treatment for anxiety in dogs.[6][7]

See also

[edit]

References

[edit]
  1. ^ a b c d e Brandt SD, Kavanagh PV, Westphal F, Stratford A, Odland AU, Klein AK, et al. (June 2020). "Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)". Drug Testing and Analysis. 12 (6): 812–826. doi:10.1002/dta.2789. PMC 9191646. PMID 32180350.
  2. ^ Tanaka R, Kawamura M, Hakamatsuka T, Kikura-Hanajiri R (2020). "[Identification of LSD Derivatives, 1cP-LSD, MIPLA and 1B-LSD in Illegal Products as Paper Sheet]". Yakugaku Zasshi. 140 (11): 1405–1413. doi:10.1248/yakushi.20-00124. PMID 33132277.
  3. ^ Vincenti F, Gregori A, Flammini M, Di Rosa F, Salomone A (September 2021). "Seizures of New Psychoactive Substances on the Italian territory during the COVID-19 pandemic". Forensic Science International. 326 110904. doi:10.1016/j.forsciint.2021.110904. PMC 8411784. PMID 34371393.
  4. ^ "Förordning (1999:58) om förbud mot vissa hälsofarliga varor".
  5. ^ "Tjugotre ämnen föreslås klassas som narkotika eller hälsofarlig vara" [Twenty-three substances are proposed to be classified as drugs or dangerous goods] (in Swedish). Folkhälsomyndigheten. December 18, 2019. Archived from the original on November 24, 2022. Retrieved May 28, 2020.
  6. ^ Hernández-Álvarez E, Borkel LF, Rojas-Hernández J, Quintana-Hernández DJ, García-Serrano I, Fernández-Borkel T, et al. (July 2025). "Evaluating the Potential of Microdosing 1cp-LSD for the Treatment of Canine Anxiety: A One-Month Case Study". Veterinary Medicine and Science. 11 (4) e70486. doi:10.1002/vms3.70486. PMC 12244264. PMID 40638522.
  7. ^ Hernández-Álvarez E, Rojas-Hernández J, Borkel LF, Quintana-Hernández DJ, Fernández-Borkel T, Henríquez-Hernández LA (September 2025). "Preliminary Findings on Low-Dose 1cp-LSD for Canine Anxiety: Exploring the Role of Owner Neuroticism and Psychopathology". Veterinary Sciences. 12 (9): 872. doi:10.3390/vetsci12090872. PMC 12474181. PMID 41012797.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=1cP-LSD&oldid=1318123631"